

Subject: RTD:P 140748Z FEB 03 DA WASHINGTON DC ARMY
AUTHORIZATION TO PROCEED WITH SMALLPOX VACCINATION UNCLAS DMDS-
TCC

PTTUZYUW RUEADWD7089 0450818-UUUU--RUERSHA RUERDGA RUERHNA
RUERICK
RUERBFA RUERBTA RUERLOU RUERCOL RUERMEN RUERALL RUERMRA RUERHFA
RUERNLX RUEREUX RUERKYA RUERSWA.

ZNR UUUUU ZYW ZOC ZEO ZUI ZUI RUCOMCA1654 0451037

P R 140748Z FEB 03

FM DA WASHINGTON DC//DAMO-AOC-CAT//

TO ALARACT

RUEADWD/DA WASHINGTON DC//DASG-HCZ//

BT

UNCLAS ALARACT 017/2003

FM DA WASHINGTON DC//DACS-ZD//

TO ALARACT

INFO CJCS WASHINGTON DC//J4//

UNCLAS ALARACT

SUBJ: ARMY AUTHORIZATION TO PROCEED WITH SMALLPOX VACCINATION
PROGRAM (SVP) FOR ARMY CIVILIAN EMPLOYEES.

REF/A/DOC/DEPSECDEF/30 SEP 02/

APMN/DEPSECDEF MEMO, SUBJ: DEPARTMENT OF DEFENSE SMALLPOX
RESPONSE

PLAN

REF/B/DOC/ASD(HA)/26 NOV 02/

APMN/ASD(HA) MEMO, SUBJ: CLINICAL POLICY FOR THE DOD SMALLPOX
VACCINATION PROGRAM (SVP)

REF/C/DOC/USD(P&R)/13 DEC 02/

APMN/USD(P&R) MEMO, SUBJ: POLICY ON ADMINISTRATIVE ISSUES
RELATED TO

PAGE 02 RUEADWD7089 UNCLAS ALARACT 017/2003

SMALLPOX VACCINATION PROGRAM (SVP)

REF/D/MSG/ASD(PA)/13 DC 02/

APMN/ASD(PA) MSG, SUBJ: WORLDWIDE PUBLIC AFFAIRS GUIDANCE FOR
THE DOD SMALLPOX VACCINATION PROGRAM (SVP)

REF/E/MSG/HQDA/212313Z DEC 02/

APMN/HQDA MSG, SUBJ: SMALLPOX VACCINATION PROGRAM (SVP)

REF/F/DOC/VCSA/10 JAN 03/

APMN/VCSA MEMO, SUBJ: ARMY SMALLPOX VACCINATION PROGRAM
IMPLEMENTATION PLAN

REF/G/CLASSIFIED MSG/HQDA/171037Z JAN 03/

APMN/HQDA CLASSIFIED MSG, SUBJ: (U) ARMY TO BEGIN IMMEDIATE
STAGE 2 SMALLPOX VACCINATIONS

1. REFS A, B, C, AND D ARE DOD SVP POLICIES AND GUIDANCE. REF E
ANNOUNCED THE DOD S SVP AND PROVIDED INITIAL SVP GUIDANCE TO THE
ARMY. REF F FORWARDED THE VCSA-APPROVED ARMY SVP IMPLEMENTATION
PLAN DIRECTING IMMEDIATE SVP EXECUTION FOR SERVICEMEMBERS ONLY.
REF G PROVIDED CLASSIFIED SVP STAGE 2 EXECUTION GUIDANCE. ALL
UNCLASSIFIED REFS ARE ON THE DOD WEBSITE, WWW.SMALLPOX.ARMY.MIL.
2. THIS MESSAGE PROVIDES ARMY AUTHORIZATION TO IMPLEMENT REF F,
THE

PAGE 03 RUEADWD7089 UNCLAS ALARACT 017/2003

ARMY SMALLPOX VACCINATION PROGRAM IMPLEMENTATION PLAN, FOR ARMY
CIVILIAN EMPLOYEES. BEFORE IMPLEMENTING FOR CIVILIAN EMPLOYEES
COVERED BY A BARGAINING UNIT, COMMANDERS MUST SATISFY ALL
BARGAINING OBLIGATIONS UNDER THE FEDERAL SERVICES LABOR
MANAGEMENT RELATIONS STATUTE AND APPLICABLE COLLECTIVE
BARGAINING AGREEMENTS.

3. IN REVIEW, THE ARMY IS NOW EXECUTING THE SVP IN THE
FOLLOWING 3
STAGES:

A. STAGE 1A: SMALLPOX RESPONSE TEAMS-DESIGNATED SPECIAL MISSION
UNITS, MEDICAL EPIDEMIOLOGICAL INVESTIGATION TEAMS, AND THE ARMY
NATIONAL GUARD CIVIL SUPPORT TEAMS.

B. STAGE 1B: SELECTED HEALTHCARE WORKERS. DOD WILL VACCINATE
SELECTED HEALTHCARE WORKERS AT MOST INSTALLATIONS, ESPECIALLY
THOSE WITH INPATIENT CAPABILITIES. THIS WILL GIVE DOD THE
CAPABILITY TO RESPOND TO A SMALLPOX ATTACK IAW THE DOD SMALLPOX
RESPONSE PLAN.

C. STAGE 2: AS PERTAINS TO U.S. CENTRAL COMMAND S MISSION,
DESIGNATED FORCES HAVING CERTAIN MISSION-CRITICAL CAPABILITIES
WILL BE VACCINATED. THIS INCLUDES CERTAIN FORCES DEPLOYED OR
ASSIGNED OVERSEAS, FORCES THAT WOULD BE EXPECTED TO DEPLOY IN A
CONTINGENCY, AND FORCES THAT ENABLE SUCH CONTINGENCY FORCES TO
DEPLOY.

4. ARMY CIVILIAN EMPLOYEES CLASSIFIED AS EMERGENCY-ESSENTIAL
UNDER

PAGE 04 RUEADWD7089 UNCLAS ALARACT 017/2003

DOD DIRECTIVE 1404.10 AND ARMY CIVILIAN EMPLOYEES WHO ARE
DESIGNATED MEMBERS OF SMALLPOX RESPONSE TEAMS ARE SUBJECT TO THE
SVP. SUBJECT TO CERTAIN MEDICAL AND ADMINISTRATIVE EXEMPTIONS
AND THE STAGED IMPLEMENTATION DESCRIBED IN PARAGRAPH 3,

VACCINATIONS ARE MANDATORY FOR ARMY CIVILIAN EMPLOYEES CLASSIFIED AS EMERGENCY ESSENTIAL UNDER DOD DIRECTIVE 1404.10 AND VOLUNTARY FOR ARMY CIVILIAN EMPLOYEES WHO ARE DESIGNATED MEMBERS OF SMALLPOX RESPONSE TEAMS.

5. MISSION ESSENTIAL SERVICES (AND ASSOCIATED CONTRACTS) MUST BE IDENTIFIED AND CONTRACTS MODIFIED TO REQUIRE THE VACCINATION OF CONTRACTOR PERSONNEL.

6. BECAUSE SMALLPOX IS CONTAGIOUS AND DEADLY, KILLING ABOUT 30% OF THOSE INFECTED, A SMALLPOX ATTACK WOULD SEVERELY DISRUPT MILITARY MISSIONS. 65% OF THE MILITARY HAVE NEVER RECEIVED SMALLPOX VACCINATION; THE REMAINING 35% DID YEARS AGO, BUT HAVE WANING IMMUNITY AND ARE SUSCEPTIBLE TO INFECTION.

A. SMALLPOX VACCINE PREVENTS SMALLPOX, BUT REQUIRES CAREFUL USE. DOD S SVP WILL USE FDA-LICENSED WYETH DRYVAX. SMALLPOX VACCINE. SMALLPOX VACCINE IS GIVEN IN ONE DOSE. DRYVAX. IS A LIVE VIRUS VACCINE USING VACCINIA VIRUS, WHICH CROSS-PROTECTS TO THE DANGEROUS SMALLPOX VIRUS, CALLED VARIOLA. EMPHASIZED: THERE IS NO SMALLPOX

PAGE 05 RUEADWD7089 UNCLAS ALARACT 017/2003

VIRUS IN THIS VACCINE, SO YOU CANNOT GET SMALLPOX FROM USING THIS VACCINE.

B. A SUCCESSFUL, EXPECTED RESPONSE TO THIS VACCINE IS A PUS-FILLED BLISTER AT THE VACCINATION SITE, WHICH SCABS OVER AND FALLS OFF, LEAVING A PERMANENT SCAR AFTER 2-3 WEEKS. MOST PEOPLE WILL EXPERIENCE MILD REACTIONS, SUCH AS SORE ARM, FEVER, HEADACHE, BODY ACHE, AND FATIGUE FROM VACCINATION. THESE SYMPTOMS MAY PEAK THE 8-12TH DAY AFTER VACCINATION. ASSESSMENT OF THE VACCINATION SITE AT DAY 6 TO 8 WILL BE IMPORTANT TO ENSURE THAT EACH VACCINATED PERSON HAS DEVELOPED PROTECTIVE IMMUNITY.

C. VERY RARELY, SMALLPOX VACCINE CAN CAUSE SERIOUS SIDE EFFECTS. IN THE PAST, BETWEEN 14-52 PEOPLE PER MILLION VACCINATED FOR THE FIRST TIME EXPERIENCED POTENTIALLY LIFE-THREATENING REACTIONS. FROM PAST EXPERIENCE, 1 OR 2 PEOPLE PER MILLION WHO RECEIVE SMALLPOX VACCINE MAY DIE AS A RESULT. DOD WILL MINIMIZE SERIOUS SIDE EFFECTS BY CAREFULLY SCREENING AND EXEMPTING PERSONNEL WHO SHOULD NOT GET SMALLPOX VACCINE, EDUCATING THOSE WHO DO ON PROPER VACCINATION SITE CARE, AND MONITORING FOR ADVERSE REACTIONS.

D. BECAUSE LIVE VACCINIA VIRUS IS PRESENT AT THE VACCINATION SITE UNTIL THE SCAB FALLS OFF, VACCINEES WILL BE TAUGHT AND GIVEN WRITTEN

PAGE 06 RUEADWD7089 UNCLAS ALARACT 017/2003

INSTRUCTIONS TO PREVENT SPREADING THE VIRUS TO OTHER PARTS OF THEIR OWN BODY OR TRANSFERRING THE VIRUS TO SOMEONE ELSE, INCLUDING THESE THREE KEY POINTS:

(1) DON T TOUCH YOUR VACCINATION SITE.

(2) IF YOU TOUCH THE VACCINATION SITE BY ACCIDENT, WASH YOUR HANDS RIGHT AWAY.

(3) DON T LET OTHERS TOUCH YOUR VACCINATION SITE OR MATERIALS THAT TOUCHED IT. MOST VACCINATION SITES CAN BE LEFT UNBANDAGED, ESPECIALLY WHEN NOT IN CLOSE CONTACT WITH OTHER PEOPLE. WHEN IN CLOSE CONTACT WITH OTHERS, SLEEVES SHOULD BE WORN COVERING THE SITE AND/OR USE OF AN ABSORBENT BANDAGE TO MAKE A TOUCH-RESISTANT BARRIER.

7. THE SVP IS A COMMANDER S RESPONSIBILITY. SUCCESSFUL SVP EXECUTION DEPENDS ON DUE ATTENTION GIVEN TO THE FOLLOWING KEY PROGRAM COMPONENTS:

A. ENSURE ARMY LEADERS (OFFICERS, NCOS, AND CIVILIAN SUPERVISORS) ARE FAMILIAR WITH THE DOD AND ARMY SVP POLICIES, REFS A THROUGH G.

B. ENSURE ARMY LEADERS ARE FAMILIAR IMMEDIATELY WITH RESOURCES AT THE DOD WEBSITE WWW.SMALLPOX.ARMY.MIL. AS WITH THE ANTHRAX VACCINE IMMUNIZATION PROGRAM, EXPERIENCE SHOWS THAT EDUCATION IS PIVOTAL TO

PAGE 07 RUEADWD7089 UNCLAS ALARACT 017/2003

SUCCESS AND SOLDIER ACCEPTABILITY. THE WEBSITE PROVIDES ARMY LEADERS

A MENU OF EDUCATION TOOLS: TOLL-FREE INFORMATION NUMBER, 1 (877) GET-VACC; EMAIL INFORMATION SERVICE, VACCINES@AMEDD.ARMY.MIL; INDIVIDUAL AND HEALTHCARE PROVIDER POWERPOINT BRIEFINGS POSTED TO THE WEBSITE; TRIFOLD EDUCATIONAL BROCHURES AND MORE. A GOOD FIRST STEP IS TO REVIEW QUESTIONS AND ANSWERS POSTED ON THE WEBSITE, AS THESE ARE THE MOST FREQUENTLY ASKED QUESTIONS BY VACCINE RECIPIENTS AND THEIR FAMILIES. THE ARMY SURGEON GENERAL S OFFICE SHIPPED EDUCATIONAL PRODUCTS WORLDWIDE TO INSTALLATION MEDICAL FACILITIES FOR LEADERS TO USE.

C. ENSURE MEDICAL PERSONNEL UNDERSTAND THE POTENTIAL ADVERSE EVENTS AFTER VACCINATION: HOW TO MINIMIZE THEM, RESPOND TO THEM, AND REPORT THEM TO THE FDA S VACCINE ADVERSE EVENT REPORTING SYSTEM (VAERS) AND IAW AR 40-562. MEDICAL PERSONNEL WILL NOT ONLY ADMINISTER THE VACCINE, BUT WILL LIKELY BE OUR FRONT LINE TO VACCINE RECIPIENTS QUESTIONS AND CONCERNS. TREAT EACH CONCERN WITH CARE: SOME SYMPTOMS FOLLOWING SMALLPOX VACCINATION MAY OR MAY NOT BE

CAUSED BY THE VACCINATION, BUT ALL DESERVE INDIVIDUAL ATTENTION. MEDICAL PERSONNEL SHOULD LIKEWISE BECOME FAMILIAR NOW WITH RESOURCES AT THE DOD WEBSITE, PARTICULARLY THE HEALTHCARE PROVIDERS

PAGE 08 RUEADWD7089 UNCLAS ALARACT 017/2003
POWERPOINT BRIEFING.

D. ENSURE ALL UNIT IMMUNIZATIONS ARE POSTED AND TRACKED IN THE MEDICAL PROTECTION SYSTEM (MEDPROS), THE HQDA STANDARD FOR TRACKING ALL INDIVIDUAL MEDICAL READINESS INDICATORS IN THE ACTIVE AND RESERVE COMPONENTS. LEADERS AT ALL LEVELS CAN TRACK INDIVIDUAL AND UNIT COMPLIANCE USING MEDPROS, A MODERN, EASY TO USE, WEB-BASED TRACKING SYSTEM, ACCESSED FROM THE WEB AT WWW.MODS.ARMY.MIL. USERS MAY REQUEST LOGON ID DIRECTLY FROM THE WEB OR BY CALLING THE MODS HELP DESK AT DSN 761-4976 OR 1-888-849-4341 FOR ASSISTANCE. IF YOU GET BEHIND ENTERING/UPDATING IMMUNIZATION DATA, NEED MEDPROS TRAINING, OR NEED HELP GETTING STARTED, CONTACT THE MODS HELP DESK FOR ASSISTANCE.

E. ENSURE YOUR MEDICAL LOGISTICS SUPPORTING ELEMENT HAS SUFFICIENT REFRIGERATION CAPACITY TO PRESERVE VACCINE INTEGRITY, INCLUDING TEMPERATURE ALARMS AND BACK UP POWER CAPACITY.

F. DOD ISSUED WORLDWIDE PUBLIC AFFAIRS GUIDANCE FOR THE SVP IN REF D. THESE MESSAGES PROVIDE GUIDANCE AND APPROVED Q AND A FOR ADDRESSING THE MEDIA AND/OR GENERAL PUBLIC.

8. HQDA POCS FOR THIS MESSAGE ARE COL RANDY RANDOLPH, COL JOHN GRABENSTEIN, OR MAJ ERIC SONES, 703-681-5101 OR DSN 761-5101, OR

PAGE 09 RUEADWD7089 UNCLAS ALARACT 017/2003
EMAIL: VACCINES@OTSG.AMEDD.ARMY.MIL.

9. EXPIRATION DATE CANNOT BE DETERMINED.

BT

#7089